Literature DB >> 26998164

Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin.

Leman Yalçintepe1, Emre Halis1, Sibel Ulku1.   

Abstract

Drug resistance is a serious challenge in cancer chemotherapy. Alterations in the intracellular concentration and homeostasis of calcium (Ca2+) may contribute to the development of drug resistance. To investigate the mechanism of drug resistance in leukemia, the present study rendered human chronic myelogenous leukemia K562 cells resistant to the cytotoxic effect of doxorubicin by progressively adapting the sensitive parental K562 cells to doxorubicin. The resulting cells were termed K562/DOX. Subsequently, the expression of two multidrug resistance proteins, P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1), was analyzed in K562/DOX cells. In addition to P-gp and MRP1, these cells also expressed cluster of differentiation (CD)38 and its active enzyme adenosine diphosphate (ADP)-ribosyl cyclase. The present study also demonstrated that K562/DOX cells responded to cyclic ADP-ribose-mediated increases in intracellular Ca2+. These data indicate that CD38 may participate in the development of drug resistance to doxorubicin in K562 cells.

Entities:  

Keywords:  ADP-ribosyl cyclase; CD38; P-glycoprotein; doxorubicin; multidrug resistance

Year:  2016        PMID: 26998164      PMCID: PMC4774626          DOI: 10.3892/ol.2016.4165

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  Emerging Roles of SIRT1 in Cancer Drug Resistance.

Authors:  Zhiqiang Wang; Wenyong Chen
Journal:  Genes Cancer       Date:  2013-03

2.  Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.

Authors:  U Kellner; L Hutchinson; A Seidel; H Lage; M K Danks; M Dietel; S H Kaufmann
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes.

Authors:  E Zocchi; L Franco; L Guida; U Benatti; A Bargellesi; F Malavasi; H C Lee; A De Flora
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

5.  Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.

Authors:  A A Kovalev; D A Tsvetaeva; T V Grudinskaja
Journal:  Exp Oncol       Date:  2013-12

Review 6.  Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers.

Authors:  H C Lee
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 7.  Human CD38: a glycoprotein in search of a function.

Authors:  F Malavasi; A Funaro; S Roggero; A Horenstein; L Calosso; K Mehta
Journal:  Immunol Today       Date:  1994-03

Review 8.  Regulation of calcium signaling by the second messenger cyclic adenosine diphosphoribose (cADPR).

Authors:  Andreas H Guse
Journal:  Curr Mol Med       Date:  2004-05       Impact factor: 2.222

Review 9.  Multiple molecular mechanisms for multidrug resistance transporters.

Authors:  Christopher F Higgins
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

10.  ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.

Authors:  Zhiqiang Wang; Zheng Liu; Xiwei Wu; Su Chu; Jinhui Wang; Hongfeng Yuan; Mendel Roth; Yate-Ching Yuan; Ravi Bhatia; WenYong Chen
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

View more
  5 in total

1.  A radioresistant fraction of acute promyelocytic leukemia cells exhibit CD38 cell-surface antigen and mRNA expression.

Authors:  Satoru Monzen; Mitsuru Chiba; Tatsuya Ueno; Yuki Morino; Kenji Terada; Hiroki Yamaya; Yoichiro Hosokawa
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

2.  Hybrid Clustered Nanoparticles for Chemo-Antibacterial Combinatorial Cancer Therapy.

Authors:  Barbara Cortese; Stefania D'Amone; Mariangela Testini; Patrizia Ratano; Ilaria Elena Palamà
Journal:  Cancers (Basel)       Date:  2019-09-10       Impact factor: 6.639

3.  MicroRNA‑145 promotes the apoptosis of leukemic stem cells and enhances drug‑resistant K562/ADM cell sensitivity to adriamycin via the regulation of ABCE1.

Authors:  Zhijun Wuxiao; Hua Wang; Qunhao Su; Haiyan Zhou; Min Hu; Shi Tao; Lu Xu; Yu Chen; Xinbao Hao
Journal:  Int J Mol Med       Date:  2020-07-15       Impact factor: 4.101

4.  Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.

Authors:  Dongxi Xiang; Sarah Shigdar; Andrew G Bean; Matthew Bruce; Wenrong Yang; Motilal Mathesh; Tao Wang; Wang Yin; Phuong Ha-Lien Tran; Hadi Al Shamaileh; Roberto A Barrero; Pei-Zhuo Zhang; Yong Li; Lingxue Kong; Ke Liu; Shu-Feng Zhou; Yingchun Hou; Aina He; Wei Duan
Journal:  Theranostics       Date:  2017-09-20       Impact factor: 11.556

5.  Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.

Authors:  Elisabetta Teodori; Laura Braconi; Silvia Bua; Andrea Lapucci; Gianluca Bartolucci; Dina Manetti; Maria Novella Romanelli; Silvia Dei; Claudiu T Supuran; Marcella Coronnello
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.